TrialClinical and translational science2018

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.

Hans Ericsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.